PUBLIC COMPANY
save$REGNREGENERON PHARMACEUTICALS, INC.
$REGN955.47+0.45%Tarrytown, NY, USupdated 1d ago
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
community read0 votes
pipeline
30
marketed
8
phase 3
9
catalysts ytd
10
approvals ytd
3
recalls ytd
0
Pipeline(30)
view full pipeline →pipeline depth30 products
1Preclinical1Phase 14Phase 29Phase 38Marketed4Unknown3pre_registration
Marketed
(atoltivimab + maftivimab + odesivimab)
Ebolavirus Infections (Ebola Hemorrhagic Fever)
MarketedEYLEA HD
wet AMD, diabetic macular edema, retinal vein occlusion
Placenta growth factorVascular endothelial growth factor A, long form
MarketedEylea
Diabetic Macular Edema
Marketedcemiplimab
Melanoma
Programmed cell death protein 1
Marketeddupilumab
Chronic Urticaria
Interleukin-4 receptor subunit alpha
Marketedevinacumab
Homozygous Familial Hypercholesterolemia (HoFH)
Marketedlinvoseltamab
Refractory Multiple Myeloma
Marketedsodium thiosulfate
Hearing Disorders
Phase 3(atisnolerbart + bremzalerbart + umesolerbart)
Birch Pollen Allergy
Phase 3cemdisiran + pozelimab
Myasthenia Gravis
Phase 3fianlimab
Metastatic Melanoma
Lymphocyte activation gene 3 protein
Phase 3freneslerbart + mevonlerbart
Cat Allergy
Upcoming
Recent(90d)
earnings (2)
Active trials
- phase1Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
- —A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
- —An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
- phase4Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
- phase3Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
- phase3A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy
- phase2Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- —An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
🐶 Hiring Signal
next earnings Jan 28, 2027
Where REGENERON PHARMACEUTICALS, INC. is staffing up — a leading indicator of pipeline and commercial priorities.
News
- Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trialRegeneron’s mid-stage success in postural orthostatic tachycardia syndrome has the company gearing up to launch a Phase 3 study in the first half of 2027.biospace · 2d ago
- 10 companies hiring in New JerseyLooking for a biopharma job in New Jersey? Jobs on BioSpace increased year over year in October, and there are hundreds of open positions posted now.biospace · 3d ago
- BioSpace 2027 Best Places to Work shines light on most admired employersThe list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.biospace · 5d ago
- The top 12 companies hiring in biopharma nowAverage jobs live on BioSpace increased year over year in October, a good sign for those eyeing a new position. If that’s you, check out the list of which companies are most actively looking to hire.biospace · 10d ago
- Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deckRegeneron executives struck an upbeat tone on an investor call Friday as the biotech posted a consensus-beating $5.1 billion in third quarter earnings and CEO Leonard Schleifer touted the company’s…biospace · 16d ago
- 8 companies hiring in New YorkLooking for a biopharma job in New York? Jobs on BioSpace have soared year over year and month over month.biospace · 17d ago
- Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, moreNew data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this…biospace · 1mo ago
- Sanofi pays Regeneron $1B upfront to continue search for Dupixent successorSanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies contend with the looming loss of exclusivity of their blockbuster drug Dupi…biospace · 1mo ago
- STAT+: Sanofi, Regeneron expand partnership after Dupixent successSanofi and Regeneron have re-upped their collaboration pact, aiming to build on the blockbuster success of the drug Dupixent.stat · 1mo ago
- FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone diseaseThe approval of Mirum Pharmaceuticals’ ALK2 inhibitor for fibrodysplasia ossificans progressiva on Friday adds a third option for patients who had long been without any treatments, joining Regenero…biospace · 1mo ago
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that